Mosapramine: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 22: | Line 22: | ||
{{stub}} | {{stub}} | ||
== Mosapramine == | |||
<gallery> | |||
File:Mosapramine.svg|Mosapramine | |||
File:Mosapramine-xtal-1993-ball-and-stick.png|Mosapramine | |||
</gallery> | |||
Latest revision as of 01:46, 20 February 2025
Mosapramine is an atypical antipsychotic used in Japan for the treatment of schizophrenia. It was approved for use in 1991. Mosapramine acts as a D2 receptor antagonist and also has high affinity for the sigma receptors, possibly playing a role in its antipsychotic effects.
Pharmacology[edit]
Mosapramine is classified as an atypical antipsychotic due to its distinct pharmacology; it has a high affinity for the D2, D3, and D4 dopamine receptors, and also for the sigma receptors. The drug has a lower affinity for the serotonin 5-HT2A and 5-HT2C receptors.
Clinical Use[edit]
In Japan, mosapramine is used for the treatment of schizophrenia. It has been found to be effective in treating both positive and negative symptoms of the disorder. The drug is usually well-tolerated, with side effects similar to those of other atypical antipsychotics.
Side Effects[edit]
Common side effects of mosapramine include drowsiness, dizziness, and dry mouth. Less common side effects can include tachycardia, hypotension, and extrapyramidal symptoms such as tremor and akathisia. Rare but serious side effects can include neuroleptic malignant syndrome and tardive dyskinesia.
